{"id":745749,"date":"2018-03-20T16:05:00","date_gmt":"2018-03-20T16:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/"},"modified":"2025-11-07T01:27:26","modified_gmt":"2025-11-07T06:27:26","slug":"merck-announces-appointment-of-jennifer-zachary-as-general-counsel","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/","title":{"rendered":"Merck Announces Appointment of Jennifer Zachary as General Counsel"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the appointment of Jennifer Zachary as general counsel,<br \/>\n      effective April 16, 2018. Zachary will be responsible for Merck\u2019s global<br \/>\n      legal, security and aviation, and environmental, health and safety<br \/>\n      organizations, and be a member of Merck\u2019s Executive Committee. She<br \/>\n      succeeds Michael J. Holston.\n    <\/p>\n<p>\n      \u201cWe are delighted to welcome Jennifer as our new general counsel. Her<br \/>\n      extensive experience across the biopharmaceutical industry makes her an<br \/>\n      exceptional addition to our team,\u201d said Kenneth C. Frazier, chairman and<br \/>\n      chief executive officer, Merck.\n    <\/p>\n<p>\n      Zachary is currently a partner at Covington &amp; Burling in the firm\u2019s<br \/>\n      food, drug, and device practice group where she advises a wide range of<br \/>\n      manufacturers and industry trade associations on FDA\u2019s requirements for<br \/>\n      the development, manufacture, and distribution of prescription and<br \/>\n      over-the-counter drugs, biologics, and medical devices. Zachary began<br \/>\n      her career in FDA\u2019s Office of Chief Counsel, where she served as an<br \/>\n      Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also<br \/>\n      served as a Special Assistant U.S. Attorney in the Civil Division of the<br \/>\n      U.S. Attorney\u2019s Office for the District of Columbia.\n    <\/p>\n<p>\n      &#8220;I\u2019m honored and excited to have the opportunity to join Merck\u2019s<br \/>\n      Executive Committee,\u201d said Zachary. \u201cI have long admired Merck for its<br \/>\n      steadfast commitment to its core values and I look forward to<br \/>\n      contributing to the company\u2019s long-term success.\u201d\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51776197&amp;newsitemid=20180320006011&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=af5c8e8876d9df7c009513df1a235351\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51776197&amp;newsitemid=20180320006011&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=33d324b14f5861b064ac2cf776a5a0e6\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51776197&amp;newsitemid=20180320006011&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=d0bb927a1dd7293eea400bb53f876610\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51776197&amp;newsitemid=20180320006011&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=789f64ba3e589590acc76076c6a0ea7e\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51776197&amp;newsitemid=20180320006011&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=12cb5ef0c601b3d7247b28342eb3d26e\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51776197&amp;newsitemid=20180320006011&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=04b416705f3a3f75237432b835541fa4\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p class=\"bwalignl\">\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51776197&amp;newsitemid=20180320006011&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=1a48d910f1b501db9653900324b9cb6c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180320006011r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Tracy Ogden, 908-740-1747<br \/>Claire Gillespie,        267-305-0932<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018. Zachary will be responsible for Merck\u2019s global legal, security and aviation, and environmental, health and safety organizations, and be a member of Merck\u2019s Executive Committee. She succeeds Michael J. Holston. \u201cWe are delighted to welcome Jennifer as our new general counsel. Her extensive experience across the biopharmaceutical industry makes her an exceptional addition to our team,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. Zachary is currently a partner at Covington &amp; Burling in the firm\u2019s food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA\u2019s requirements for the development, manufacture, and distribution of prescription and over-the-counter drugs, biologics, and medical devices. Zachary began her career in FDA\u2019s Office<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745749","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Appointment of Jennifer Zachary as General Counsel - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Appointment of Jennifer Zachary as General Counsel - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018. Zachary will be responsible for Merck\u2019s global legal, security and aviation, and environmental, health and safety organizations, and be a member of Merck\u2019s Executive Committee. She succeeds Michael J. Holston. \u201cWe are delighted to welcome Jennifer as our new general counsel. Her extensive experience across the biopharmaceutical industry makes her an exceptional addition to our team,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. Zachary is currently a partner at Covington &amp; Burling in the firm\u2019s food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA\u2019s requirements for the development, manufacture, and distribution of prescription and over-the-counter drugs, biologics, and medical devices. Zachary began her career in FDA\u2019s Office\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\\\/\",\"name\":\"Merck Announces Appointment of Jennifer Zachary as General Counsel - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-03-20T16:05:00+00:00\",\"dateModified\":\"2025-11-07T06:27:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Appointment of Jennifer Zachary as General Counsel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Appointment of Jennifer Zachary as General Counsel - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Appointment of Jennifer Zachary as General Counsel - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018. Zachary will be responsible for Merck\u2019s global legal, security and aviation, and environmental, health and safety organizations, and be a member of Merck\u2019s Executive Committee. She succeeds Michael J. Holston. \u201cWe are delighted to welcome Jennifer as our new general counsel. Her extensive experience across the biopharmaceutical industry makes her an exceptional addition to our team,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. Zachary is currently a partner at Covington &amp; Burling in the firm\u2019s food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA\u2019s requirements for the development, manufacture, and distribution of prescription and over-the-counter drugs, biologics, and medical devices. Zachary began her career in FDA\u2019s Office","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:26+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/","name":"Merck Announces Appointment of Jennifer Zachary as General Counsel - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-03-20T16:05:00+00:00","dateModified":"2025-11-07T06:27:26+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-appointment-of-jennifer-zachary-as-general-counsel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Appointment of Jennifer Zachary as General Counsel"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"68b4359b-5b26-455f-b2b4-41561e29e24b","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745749\/revisions"}],"predecessor-version":[{"id":3675109,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745749\/revisions\/3675109"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745749"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}